本帖最后由 老马 于 2013-3-13 13:43 编辑 7 Q$ `: J( q J) _( k' _
% { D# G1 V1 ]# Y4 [: y2 z健择（吉西他滨）+顺铂+阿瓦斯汀
8 |) e; k. t! d4 c+ u3 d Gemzar +Cisplatin + Avastin
5 h l3 ^0 G" k) q; h! h1 ~http://annonc.oxfordjournals.org/content/21/9/1804.full
3 g* C* ~3 z& v# j! l3 _/ JOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) , i7 }8 @, S1 u$ J2 W- A a
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
" u3 [: r5 o$ M: rResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
+ n; w/ m+ ^" d$ A
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 611)
: R6 a5 d; k2 x! l8 X& I. p华为网盘附件： F: a+ k; s* p2 [
【华为网盘】ava.JPG: I% m: L) I" _
|
显身卡
